HDT Bio’s repRNA/LION Technology Licensed by MalarVx for Novel Malaria Vaccine

HDT Bio, a leader in advanced RNA vaccine technologies, is partnering with MalarVx to advance malaria vaccines using its proprietary self-amplifying RNA (repRNA) and LION nanoparticle delivery systems. With malaria causing 597,000 deaths in 2023, HDT Bio’s LION platform offers a proven ability to generate strong, durable immune responses, addressing the urgent need for effective malaria prevention.